1997 B.E., Zhengzhou University, China 2002 M.E., Zhengzhou University, China 2005 Ph.D., Tianjin University, China 2005-2007 Postdoc, Tianjin University, China 2007-2010 Principal scientist, Novartis Institutes for BioMedical Research, China 2010-2013 Professor, Shanghai Institute of Pharmaceutical Industry, China 2013- Professor, State key laboratory of Bioreactor Engineering, ECUST, China

一直从事药物晶体工程技术研究，提出应用机器学习和数据挖掘技术，寻找与药物固体形态有内禀关系的分子描述符，归纳获得不同描述符对各种固体形态产生的影响规律，并提高新化合物预测效率，指导实验研究；将外源物理场引入药物固体形态的发现过程中，以全面获得药物的潜在固体形态；提出相变前超分子组装调控以及晶核微环境的控制理念，结合过程分析技术，开发特定固体形态药物的新工艺及产业化应用

1. Zhu B, Fang X, Zhang Q, Mei X*, Ren G*. Study of crystal structures, properties, and form transformations among a polymorph, hydrates, and solvates of apatinib. Cryst. Growth Des., 2019, 19, 3060-3069.

2. Zhu B, Wang J-R, Zhang Q, Li M, Guo C, Ren G*, Mei X*. Stable cocrystals and salts of the antineoplastic drug apatinib with improved solubility in aqueous solution. Cryst. Growth Des., 2018, 18, 4701-4714.

3. Zhu B, Zhang Q, Ren G*, Mei X*. Solid-state characterization and insight into transformations and stability of apatinib mesylate solvates. Cryst. Growth Des., 2017, 17, 5994-6005.

4. Chen W, et al., Ren G*, Miao Z*, Li J*. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy. Eur. J. Med. Chem., 2017, 138, 514-531.

5. Zhu B, Wang J-R, Ren G*, Mei X*. Polymorphs and hydrates of apatinib mesylate: insight into the crystal structures, properties, and phase transformations. Cryst. Growth Des., 2016, 16, 6537-6546.

6. Qi M-H, et al., Ren G-B*. Estimating thermodynamic stability relationship of polymorphs of sofosbuvir. Cryst. Growth Des., 2015, 15, 5062-5067.